• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • 中文 (中国)
  • English
Worcester HIV Vaccine

Worcester HIV Vaccine

  • Home
  • Our Science
    • PDPHV candidate
    • Vaccine approach
    • Our Clinical Trials
    • Preclinical studies
    • Publications
  • About WHV
    • Our Mission
    • Our History
    • Our Team
    • Our Advisors
    • Safety Monitoring Board
  • News
  • Contact us

HVTN 124 immunogenicity data presented at the 2021 HVTN Full Group Meeting

May 6, 2021

On May 6th, Dr. Shan Lu gave a presentation on behalf of the HVTN124 protocol team during a plenary session that was part of the larger 2021 HVTN Full Group Meeting. He shared a summary of the excellent immunogenicity data obtained from the multi-center phase 1a study testing the investigational HIV vaccine candidate PDPHV, a polyvalent DNA/Protein HIV Vaccine. To read the whole press release, click on the link below.

HVTN124-Program-Immunogenicity-ResultsDownload

Filed Under: News

Footer

© 2019 Worcester HIV Vaccine

WHV Logo